Cite
HARVARD Citation
Cheong, H. et al. (2019). First‐in‐Asian Phase I Study of the Anti‐Fibroblast Growth Factor 23 Monoclonal Antibody, Burosumab: Safety and Pharmacodynamics in Adults With X‐linked Hypophosphatemia. JBMR plus. p. n/a. [Online].